MoonLake Immunotherapeutics Financial Results
MoonLake Immunotherapeutics reported Q3 2026 financial results and announced the submission of a Biologics License Application (BLA) to the FDA for sonelokimab in hidradenitis suppurativa. The company ended the quarter with $498.5 million in cash and equivalents, providing a projected cash runway into mid-2028.
- Term
- Q3 2026